Technology
32Biosciences is focused on gastrointestinal (GI) diseases initially centered on the colon, addressing high unmet medical needs in prevention and treatment with a first-in-class therapeutic and a novel discovery platform.
Scientific Expertise
At 32 Biosciences, our approach is grounded in decades of visionary research led by our renowned scientific co-founders—John Alverdy, MD, Eugene Chang, MD, and Joseph Pierre, PhD. As globally recognized experts in gastrointestinal disease, their pathbreaking work includes over 650 peer-reviewed publications and $126M in NIH funding, forming the foundation of our innovative solutions.
Our transformative platform technologies are further propelled by strategic collaborations with the University of Chicago’s Duchossois Family Institute and Pritzker School of Molecular Engineering.
Our Solution: Two Integrated Platforms
CS Therapeutic Pipeline (MIMs)
Our Mucosal Immune Modulator (MIM) therapeutics – including lead asset CS-0003 – modulate the gut mucosal-immune interface to:
- Coat and stabilize the mucosal barrier
- Suppress virulence gene activation (PstS-PhoB)
- Reduce inflammation
- Prevent GI surgical site infections and related complications
Expanded Mechanism-of-Action Sequence:
- STEP 1 – CS-0003 coats the GI tract, stabilizing bacterial behavior under stress
- STEP 2 – CS-0003 prevents bacterial virulence gene expression via PstS-PhoB
- STEP 3 – CS-0003 reduces microbial “danger signals” senses by innate immunity
- STEP 4 – The mucosal immune response normalizes (immune modulation, not suppression)
- STEP 5 – Restored homeostasis at the host-microbiome interface promotes healing
GI Discovery Platform
A metabolomic-based platform measuring gut microbiome function and mucosal-immune activity to enable
- Screening/Management Tool development (e.g., GB-0001)
- Patient stratification
- Companion diagnostics
- Therapeutic discovery